Targets › CLN7
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout Feb 2028.
Outward-rectifying chloride channel involved in endolysosomal chloride homeostasis, membrane fusion and function. Conducts chloride currents up to hundreds of picoamperes. (UniProt, Q8NHS3)
Open in Phaseline: the race on CLN7, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Benjamin Greenberg | AAV9/CLN7 AAV9-mediated gene therapy delivering CLN7 | CLN7 | Phase 1 | CLN7 | Feb 2028 |
CLN7 (1)
other (1)
Benjamin Greenberg (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.